Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03231397 · ClinicalTrials.gov registry record · Phase 4
Predictors of AAA Expansion and/or Rupture
A Phase 4 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03231397: Clinical Trial Phase 4 study, sponsored by Washington University School of Medicine.
NCT03231397 is a Phase 4 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03231397, a Phase 4 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or because they do not have an AAA (control group). The purpose of this research study is to further study, through FEA, changes that occur in the mechanical properties of the aortic wall. The investigator will compare two radiotracers, 18F-FDG and 11C-PBR28 to determine if one provides more useful and reliable information about inflammation. 18F-FDG and 11C-PBR28 are radioactive drugs that will be used for imaging during the PET-CT scan. The investigator will also compare the results describing the mechanical properties of the AAA wall to the degree of inflammation in that wall as determined by PET-CT imaging to define new and better predictors of AAA growth and/or rupture.
Primary Outcome
Aortic inflammation as demonstrated by uptake of radiotracer
Interventions
- DRUG Assess AAA rupture risk by PET-CTA scans
- DRUG 18F-fludeoxyglucose (FDG)
- DIAGNOSTIC_TEST 11C-PBR28
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 4 |
Why NCT03231397 stopped before completion
NCT03231397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Assess AAA rupture risk by PET-CTA scans is the first listed.
NCT03231397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03231397 about?
NCT03231397 is a clinical study titled "Predictors of AAA Expansion and/or Rupture". Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or because they do not have an AAA (control group). The purpose of this research study is to further study, through FEA, changes that occur in the mechanical properties of the aortic wall. The investigator will...
What is the current status of trial NCT03231397?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2017-08-01. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT03231397?
The interventions under investigation include: Assess AAA rupture risk by PET-CTA scans (DRUG), 18F-fludeoxyglucose (FDG) (DRUG), 11C-PBR28 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03231397?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03231397's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI